Cost-Effectiveness Analysis of Lenvatinib as a Treatment for Radioactive Iodine Refractory Differentiated Thyroid Cancer in the United States
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1595
https://www.valueinhealthjournal.com/article/S1098-3015(16)01663-6/fulltext
Section Title :
Cancer - Cost Studies
Section Order :
318
First Page :
A151
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01663-6&doi=10.1016/j.jval.2016.03.1595